Cantor Fitzgerald Predicts Gilead Sciences FY2025 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Gilead Sciences in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of $7.24 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $80.00 price target on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.36 per share.

GILD has been the topic of several other reports. Truist Financial lifted their price target on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. UBS Group lifted their price target on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $97.96.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $93.04 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The business’s 50 day moving average is $91.62 and its two-hundred day moving average is $84.57. The company has a market cap of $115.95 billion, a P/E ratio of 1,033.78, a P/E/G ratio of 1.29 and a beta of 0.18. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.29 EPS.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently modified their holdings of the business. nVerses Capital LLC bought a new stake in shares of Gilead Sciences in the third quarter worth about $25,000. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares in the last quarter. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $29,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the second quarter worth about $33,000. Finally, Quarry LP bought a new stake in shares of Gilead Sciences in the second quarter worth about $43,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 over the last 90 days. 0.29% of the stock is owned by company insiders.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.